A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
Quantara AI launches a continuous platform designed to estimate the financial impact of cyber risk as companies move beyond periodic assessments
Updated
February 20, 2026 6:43 PM
A person tightrope walking between two cliffs. PHOTO: UNSPLASH
Cyber risk is increasingly treated as a financial issue. Boards want to know how much a cyber incident could cost the company, how it could affect earnings, and whether current security spending is justified.
Yet many organizations still measure cyber risk through periodic reviews. These assessments are often conducted once or twice a year, supported by consultants and spreadsheet models. By the time the report reaches senior leadership, the company’s systems may have changed and new threats may have emerged. The way risk is measured does not always match how quickly it evolves.
This gap is where Quantara AI is positioning its new platform. Quantara AI, a Boise-based cybersecurity startup, has introduced what it describes as the industry’s first persistent AI-powered cyber risk solution. The system is designed to run continuously rather than rely on occasional assessments.
The company’s core argument is straightforward: not every security weakness carries the same financial consequence. Instead of ranking issues only by technical severity, the platform analyzes active threats, identifies which company systems are exposed, and estimates how much money a successful attack could cost. It uses statistical models, including Value at Risk (VaR), to calculate potential losses. It also estimates how specific security improvements could reduce that projected loss.
The timing aligns with a broader market shift. International Data Corporation (IDC) projects that by 2028, 40% of enterprises will adopt AI-based cyber risk quantification platforms. These tools convert security data into financial estimates that can guide budgeting and investment decisions. The forecast reflects growing pressure on security leaders to present risk in terms that boards and regulators understand.
Traditional compliance and risk management systems often focus on meeting regulatory standards. Vulnerability management programs typically score weaknesses based on technical characteristics. Consultant-led risk studies provide detailed analysis, but they are usually performed at set intervals. In fast-changing threat environments, that model can leave decision-makers working with outdated information.
Quantara’s platform attempts to replace that periodic process with continuous measurement. It brings together threat data, internal system information and financial modeling in one system. The goal is to show, at any given time, which specific weaknesses could lead to the largest financial losses.
Cyber risk quantification as a concept is not new. What is changing is the expectation that these calculations be updated regularly and tied directly to financial decision-making. As cyber incidents carry clearer monetary consequences, companies are looking for ways to measure exposure with greater precision.
The broader question is whether enterprises will shift fully toward continuous, AI-driven risk analysis or continue relying on periodic external assessments. What is clear is that cybersecurity discussions are moving closer to financial reporting — and tools that estimate potential loss in dollar terms are becoming central to that shift.